Hemostatic tests in patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.56294/saludcyt2024981Keywords:
Diabetes Mellitus 2, Blood Coagulation, Blood Coagulation Factors, Hemostatic AlterationsAbstract
Introduction: type 2 Diabetes Mellitus (DM2), or non-insulin-dependent, is a chronic disease characterized by insulin resistance or reduced insulin levels, which in turn contribute to high glucose levels. This condition, together with the associated chronic inflammation, generates several complications, one of them is an imbalance in the hemostatic system.
Objective: to identify laboratory hemostatic tests and their clinical usefulness in patients with type 2 Diabetes Mellitus.
Methods: a bibliographic review was carried out in various databases of interest, including articles published in the last 5 years, in addition to those articles published before 2019 that limited relevant information on the topic.
Development: original articles that analyzed hemostatic tests in patients with DM2 were reviewed and it was established that the main tests that are altered are TTP, MPV, fibrinogen, PAI-1, VWF and DD, since they have presented consistent results in different research.
Conclusions: it is necessary to perform hemostatic tests in patients with DM2, since it has been seen that untreated patients may present thrombotic disorders that, in the long term, can generate cardiovascular alterations
References
1. Centers for Disease Control and Prevention. Datos breves sobre la diabetes | Basics | Spanish | Diabetes | CDC [Internet]. 2022 [cited 2024 Mar 16];Available from: https://www.cdc.gov/diabetes/spanish/basics/quick-facts.html
2. Heredia M, Gallegos E, Heredia M, Gallegos E. Riesgo de diabetes mellitus tipo 2 y sus determinantes. Enfermería Global 2022;21(65):179–202.
3. Organización Panamericana de la Salud. Diabetes - OPS/OMS | Organización Panamericana de la Salud [Internet]. 2023 [cited 2024 Mar 16];Available from: https://www.paho.org/es/temas/diabetes
4. Freire W, Luzuriaga M, Belmont P, Mendieta M, Jaramillo K, Romero N, et al. Encuenta Nacional de Salud y Nutrición. Tomo I. 2014.
5. Pérez J, Gallego N, Velarde C, Franco L, Valencia A. Efecto de la hiperglucemia en el síndrome coronario agudo y sus implicaciones en el tratamiento antiagregante plaquetario. Iatreia 2019;32(2):113–25.
6. Burgos R, Joaquim C, Puiggrós Llop C, Chicharro Serrano L, Burgos Peláez R. Diabetes mellitus tipo 2 crónica. Nutrición Hospitalaria 2010;3(1):35–45.
7. Fernández CIJ, Fernández CIJ, Pereira YAM, Chang ASO, Olmedo SIG, Gaete MCA. Fisiopatología y alteraciones clínicas de la diabetes mellitus tipo 2: revisión de literatura. Nova 2022;20(38):65–103.
8. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1).
9. Sánchez J, Sánchez N. Epidemiología de la diabetes mellitus tipo 2 y sus complicaciones. Revista Finlay 2022;12(2):168–76.
10. Rodriguez S, Guzmán S, Barreno S, Rubio B, Nava A. Hemostasia y factores asociados a tendencia trombótica. Revista Mexicana de Patología Clínica y Medicina de Laboratorio 2019;66(4):227–33.
11. Panizo E, Páramo J. Fisiología de la hemostasia. Pediatría Integral 2021;5.
12. Li X, Weber N, Cohn D, Hollmann M, Devries J, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. Journal of Clinical Medicine 2021, Vol 10, Page 2419 2021;10(11):2419.
13. Palella E, Cimino R, Pullano S, Fiorillo A, Gulletta E, Brunetti A, et al. Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control. International Journal of Environmental Research and Public Health 2020, Vol 17, Page 300 2020;17(1):300.
14. Van der Toorn F, de Mutsert R, Lijfering W, Rosendaal F, Van Hylckama A. Glucose metabolism affects coagulation factors: The NEO study. Journal of Thrombosis and Haemostasis 2019;17(11):1886–97.
15. O’Hara A, Pozin J, Darki A, Siddiqui F, Hoppensteadt D, Walenga J, et al. Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis 2023;29.
16. Selleh P, Anto E, Boadu W, Sackey B, Boateng L, Nkansah C, et al. Quality of glycemic control in type 2 diabetes mellitus (T2DM) and its association with markers of coagulation and inhibitors of fibrinolysis: A case–control study in the Upper West Region, Ghana. Health Science Reports 2023;6(6).
17. Ambelu Y, Shiferaw M, Abebe M, Enawgaw B. Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study. Journal of diabetes and metabolic disorders 2018;17(2):117–21.
18. Inoue H, Saito M, Kouchi K, Asahara S ichiro, Nakamura F, Kido Y. Association between mean platelet volume in the pathogenesis of type 2 diabetes mellitus and diabetic macrovascular complications in Japanese patients. Journal of diabetes investigation 2020;11(4):938–45.
19. Ulutas K, Dokuyucu R, Sefil F, Yengil E, Sumbul A, Rizaoglu H, et al. Evaluation of mean platelet volume in patients with type 2 diabetes mellitus and blood glucose regulation: a marker for atherosclerosis? International Journal of Clinical and Experimental Medicine 2014;7(4):955.
20. Xu F, Qu S, Wang L, Qin Y. Mean platelet volume (MPV): new diagnostic indices for co-morbidity of tuberculosis and diabetes mellitus. BMC Infectious Diseases 2021;21(1).
21. Li Z, Qi C, Jia Z, Zhen R, Ren L, Jia Y, et al. The Correlation Between Estimated Glucose Disposal Rate and Coagulation Indexes in Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2022;15:2643.
22. Lena A, Raymondo S. Hemostasia y Trombosis Comunicación breve Evaluation about coagulation physiological inhibitors in type 2 diabetic patients Acta Bioquímica Clínica Latinoamericana. Acta Bioquímica Clínica Latinoamericana 2007;41(2):213–8.
23. Barrantes A, Gei O, Saenz G, Fonseca J, Schosinski K. Modificaciones De La Hemostasia En La Diabetes Mellitus Del Adulto. Revista Costarricense de Ciencias Medicas 2015;6(2):87–95.
24. Zhao Y, Zhang J, Zhang J, Wu J. Diabetes Mellitus Is Associated with Shortened Activated Partial Thromboplastin Time and Increased Fibrinogen Values. PLoS ONE 2011;6(1):16470.
25. Wieczór R, Wieczór A, Kulwas A, Rość. Type 2 Diabetes and Cardiovascular Factors Contrasted with Fibrinolysis Disorders in the Blood of Patients with Peripheral Arterial Disease. Medicina 2019;55(7).
26. Contreras F, Barreto N, Jiménez S, Terán L, Castillo A, García M, et al. Complicaciones Macrovasculares en Diabetes Tipo 2 Asociación con Factores de Riesgo. Archivos Venezolanos de Farmacología y Terapéutica 2000;19(2):112–6.
27. Iqbal A, Greig M, Arshad M, Julian T, Ee Tan S, Elliott J. Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K. Diabetes Research and Clinical Practice 2021;178:108955.
28. Nkansah C, Addai O, Mensah K, Owusu M, Ephraim R, Adu P, et al. Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana. PLoS ONE 2021;16(4).
29. Li L, Shi Z, Ma L, Lu Y. Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes. Annals of Palliative Medicine 2021;10(1):66471–671.
30. Karasek D, Spurna J, Kubickova V, Krystynik O, Cibickova L, Schovanek J, et al. Association of pigment epithelium derived factor with von Willebrand factor and plasminogen activator inhibitor 1 in patients with type 2 diabetes. Physiological research 2019;68(3):409–18.
31. Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2009;18(4):266–71.
32. Li F, Yuan L, Shao N, Yang X, Yang S, He L, et al. Changes and significance of vascular endothelial injury markers in patients with diabetes mellitus and pulmonary thromboembolism. BMC Pulmonary Medicine 2023;23(1).
33. Macarena N, Alvarado H, Andrea T, Ríos N. Actividad procoagulante del factor tisular plaquetario en pacientes con diabetes mellitus tipo II. 2015;
34. Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, et al. D-dimer as a predictor of cardiovascular outcomes in patients with diabetes mellitus. BMC Cardiovascular Disorders 2022;22(1).
35. McBane R, Hardison R, Sobel B. Comparison of Levels of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer in Various Age Decades in Patients with Type-2 Diabetes Mellitus and Stable Coronary Artery Disease (From the BARI 2d Trial). The American journal of cardiology 2010;105(1):17.
Published
Issue
Section
License
Copyright (c) 2024 Nathaly Beleén Freire Sánchez , Daniela Alexandra Rosero Freire (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
